This is a confirmation of "POOL TESTING" FROM THE FDA FDA FDA, it is no longer a suggestion or "WE SHOULD DO" kind of discussion. The current administration and FDA are planning to test everyone to control the Virus Spread. Although, if 1 in 4 people get tested positive, all of them will have to re-test again. However, ""concern that combining samples may make it more difficult to detect positives, since pooling in the laboratory dilutes any viral material present in the samples,"
This also means, the vaccine will take some more time to perform trial, they won't cut corner on safety, and until gather more data from volunteers. TESTING WILL BE THE NEXT BIG THING UNTIL VACCINE IS DONE SAFELY(We are nowhere near this, and not many people are willing to be lab rat of the new Vaccine).
Now, on TTOO, the past 2 weeks, we have some serious organic gain, which meant, No impulsive pump and dump, just a gradual amount of shares being pumped in after the current testing revenue was upgraded earlier this week from 10-20B to 75-100B revenue.The amount of Shares floating around ran drier and drier.
WE DONT HAVE IMPULSIVE DAY LIKE JULY 1st. Roughly over 30m shares were dumped on July 1st(1 SINGLE DAY), that caused the Panic-selling from small-med traders til July 7th. Since then we have roughly 4m shares pumped in on July 7th, and gradually increased until NOW(2-7m shares added daily). A healthy sign from people who did their DD on TTOO, and see the current potential market on Covid-19 testing.
Let me remind you that: -TTOO HAS REAL REVENUE ON SEPSIS ALONE -TTOO HAS REAL PRODUCT and COVID-19 PANEL IS NOT THE ONLY PRODUCT THEY HAVE! -TTOO REVENUE BEAT ALL ANALYSIS and on UPWARD TREND( THAT IS WITHOUT THE NEW COVID-19 PANEL SALE) -TTOO HAS 36.5M CASH ON HAND -TTOO TESTING IS THE BEST TESTING SYSTEM ON THE MARKET RIGHT NOW that give result in LESS THAN 2 HOURS. -TTOO NEVER DID ANY RESERVE SPLIT like other Covid-19 related, because TTOO RESPECT US ENOUGH TO NOT DILUTE THEIR SHARES VALUE AKA YOU! -TTOO CEO John Sperzel(NEW since JAN 9,2020) know how to bring TTOO testing panel to the market, he used to be CEMI CEO.
"T2 Biosystems stock has undergone multiple analysts rating changes in the recent past. T2 Biosystems stock Target Raised by Canaccord Genuity on 7/16/2020. In a note to investors, the firm issued a new target price of $4.00. The analysts previously had $3.00 target price. Canaccord Genuity’s price target would indicate a potential upside of 153.16% from the stock’s previous close."
Market Data 
Markets 
AI
